Literature DB >> 11950783

Glucuronidation of the dietary fatty acids, phytanic acid and docosahexaenoic acid, by human UDP-glucuronosyltransferases.

Joanna M Little1, Lisa Williams, Jing Xu, Anna Radominska-Pandya.   

Abstract

Linoleic acid has recently been shown to be glucuronidated in vitro by human liver and intestinal microsomes and recombinant UGT2B7. In the present study, the dietary fatty acids (FA), phytanic acid (PA), and docosahexaenoic acid (DHA) have been used as substrates for human UDP-glucuronosyltransferases (UGTs). Both compounds were effectively glucuronidated by human liver microsomes (HLM; 1.25 +/- 0.36 and 1.12 +/- 0.32 nmol/mg x min for PA and DHA, respectively) and UGT2B7 (0.71 and 0.53 nmol/mg x min). Kinetic analysis produced relatively low K(m) values for PA with both HLM and UGT2B7 (149 and 108 microM, respectively). The K(m) for DHA glucuronidation by HLM (460 microM) was considerably higher than that for UGT2B7 (168 microM), suggesting the involvement in microsomes of other UGT isoforms in addition to UGT2B7. Glucuronidation of PA and DHA by gastrointestinal microsomes from 16 human subjects was determined. In general, both PA and DHA were glucuronidated by gastric and intestinal microsomes, and activity toward both substrates was lowest in the stomach, increased in the small intestine, and lower in the colon. However, there were large interindividual variations in UGT activity toward both substrates in all segments of the intestine, as has been seen with other substrates. Thus, PA and DHA are effective in vitro substrates for human liver, gastric and intestinal microsomes, and glucuronidation may play a role in modulating the availability of these FA as ligands for nuclear receptors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11950783     DOI: 10.1124/dmd.30.5.531

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

1.  Phenylalanine(90) and phenylalanine(93) are crucial amino acids within the estrogen binding site of the human UDP-glucuronosyltransferase 1A10.

Authors:  Athena Starlard-Davenport; Yan Xiong; Stacie Bratton; Anna Gallus-Zawada; Moshe Finel; Anna Radominska-Pandya
Journal:  Steroids       Date:  2006-12-15       Impact factor: 2.668

2.  Human UDP-Glucuronosyltransferases: Effects of altered expression in breast and pancreatic cancer cell lines.

Authors:  Centdrika R Dates; Tariq Fahmi; Sebastian J Pyrek; Aiwei Yao-Borengasser; Barbara Borowa-Mazgaj; Stacie M Bratton; Susan A Kadlubar; Peter I Mackenzie; Randy S Haun; Anna Radominska-Pandya
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

3.  Novel identification of UDP-glucuronosyltransferase 1A10 as an estrogen-regulated target gene.

Authors:  Athena Starlard-Davenport; Beverly Lyn-Cook; Anna Radominska-Pandya
Journal:  Steroids       Date:  2007-09-29       Impact factor: 2.668

4.  Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression.

Authors:  Dione Gardner-Stephen; Jean-Marie Heydel; Amit Goyal; Yuan Lu; Wen Xie; Tim Lindblom; Peter Mackenzie; Anna Radominska-Pandya
Journal:  Drug Metab Dispos       Date:  2004-03       Impact factor: 3.922

5.  Identification of UDP-glucuronosyltransferase 1A10 in non-malignant and malignant human breast tissues.

Authors:  Athena Starlard-Davenport; Beverly Lyn-Cook; Anna Radominska-Pandya
Journal:  Steroids       Date:  2008-02-03       Impact factor: 2.668

6.  Effects of fatty acids on benzo[a]pyrene uptake and metabolism in human lung adenocarcinoma A549 cells.

Authors:  Rola Barhoumi; Youssef Mouneimne; Robert S Chapkin; Robert C Burghardt
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

7.  A Gilbert syndrome-associated haplotype protects against fatty liver disease in humanized transgenic mice.

Authors:  Steffen Landerer; Sandra Kalthoff; Stefan Paulusch; Christian P Strassburg
Journal:  Sci Rep       Date:  2020-05-26       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.